moneyheap
AMLX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) stock moving?
Amylyx's main catalyst is the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, which met its primary endpoint with a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003) and met all secondary endpoints. The company remains on track to submit its NDA by year-end 2026, with a possible 2027 launch if approved, and will present the data as a late-breaking oral at ObesityWeek on November 15. Q3 EPS of $(0.38) was in line, and an upsized offering with about $545M in net proceeds strengthened the balance sheet but added share supply. The stock fell 6.1% to $27.62 on November 5 on 2.21M shares, the highest volume in the 30-day window, then recovered on lower volume to close at $30.91 on November 10, near the 30-day high of $31.22. Mizuho raised its price target to $39 from $38 and kept Outperform, which implies about 26% upside from the last close. Key risks are the still-pending NDA filing, the FDA review that lies beyond the 6-month window, and dilution from the recent offering.
News behind the analysis
- Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39Mizuho kept its Outperform rating on Amylyx and raised its price target to $39.
- Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $39 From $38, Maintains Outperform RatingMizuho raised its Amylyx price target from $38 to $39 and kept its Outperform rating.
- Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsAmylyx reported positive Phase 3 LUCIDITY topline data for avexitide in post-bariatric hypoglycemia and a strengthened balance sheet after an upsized offering with about $545M in net proceeds.
- Amylyx Pharma Q3 EPS $(0.38), InlineAmylyx reported a third-quarter EPS loss of $(0.38), in line with expectations.
- Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026Amylyx will host an investor event at ObesityWeek 2026 featuring experts in post-bariatric hypoglycemia.
- Amylyx Pharmaceuticals to Participate in Upcoming November Investor ConferencesAmylyx will take part in investor conferences scheduled for November 2026.
- Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial ResultsAmylyx scheduled its third-quarter 2026 results release for November 5, 2026.
About Amylyx Pharmaceuticals, Inc. Common Stock
Amylyx Pharmaceuticals is a Cambridge, Massachusetts biotech company. Its lead drug candidate is avexitide, which is being developed for post-bariatric hypoglycemia (dangerously low blood sugar that can follow weight-loss surgery). The company previously sold an ALS drug, Relyvrio, but pulled it from the market after a failed Phase 3 trial, and in 2026 avexitide reported positive Phase 3 LUCIDITY results.
How it makes money
At the moment Amylyx has essentially no product revenue and runs at a loss, with a net loss of about $45 million in Q3 2026. It pays for research and preparation for a possible avexitide launch with cash raised from investors, including an upsized stock offering of about $500 million in August 2026. If avexitide is approved, sales of the drug would become its main source of revenue.
What usually moves AMLX
- FDA review and approval decision for avexitide
- Avexitide launch preparation and commercial uptake
- Clinical trial data from pipeline programs
- Cash burn and future share offerings (dilution)
- Biotech sector sentiment